Drug
GB-0139 clinical trials
Also written TD139.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Galecto Biotech AB (2) · University of Edinburgh (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GB-0139 is read from its arms, and is right about nine times in ten.
Testing it · 3
- DEFINE - Evaluating Therapies for COVID-19CompletedPhase 1/2University of EdinburghNCT04473053Written as TD139
- A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2Galecto Biotech ABNCT03832946Written as GB0139
- RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF PatientsCompletedPhase 1/2Galecto Biotech ABNCT02257177Written as Inhaled TD139
Codes
What other systems call GB-0139 · ClinicalTrials.gg INT001471
- MeSH (NLM) C000711747GB-0139One source NLM
- UNII (FDA) 60Y0GUO72BOLITIGALTINConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711747 | GB-0139 | One source NLM |
| UNII (FDA) | 60Y0GUO72B | OLITIGALTIN | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.